IL288877B1 - קווי תאים לייצור ברמה גבוהה של תרופות מבוססות חלבון - Google Patents
קווי תאים לייצור ברמה גבוהה של תרופות מבוססות חלבוןInfo
- Publication number
- IL288877B1 IL288877B1 IL288877A IL28887721A IL288877B1 IL 288877 B1 IL288877 B1 IL 288877B1 IL 288877 A IL288877 A IL 288877A IL 28887721 A IL28887721 A IL 28887721A IL 288877 B1 IL288877 B1 IL 288877B1
- Authority
- IL
- Israel
- Prior art keywords
- cells
- cell
- protein
- cell line
- population
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 128
- 102000004169 proteins and genes Human genes 0.000 title claims description 101
- 238000004519 manufacturing process Methods 0.000 title claims description 55
- 239000003814 drug Substances 0.000 title claims description 8
- 210000004027 cell Anatomy 0.000 claims description 388
- 238000000034 method Methods 0.000 claims description 52
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 28
- 230000014616 translation Effects 0.000 claims description 28
- 108700019146 Transgenes Proteins 0.000 claims description 23
- 210000002288 golgi apparatus Anatomy 0.000 claims description 20
- 230000004927 fusion Effects 0.000 claims description 17
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 14
- 239000003550 marker Substances 0.000 claims description 14
- 239000012531 culture fluid Substances 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 230000013595 glycosylation Effects 0.000 claims description 6
- 238000006206 glycosylation reaction Methods 0.000 claims description 6
- 210000003734 kidney Anatomy 0.000 claims description 6
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 6
- 108020001507 fusion proteins Proteins 0.000 claims description 5
- 102000037865 fusion proteins Human genes 0.000 claims description 5
- 230000003287 optical effect Effects 0.000 claims description 5
- 230000028327 secretion Effects 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 230000003322 aneuploid effect Effects 0.000 claims description 3
- 208000036878 aneuploidy Diseases 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 210000003850 cellular structure Anatomy 0.000 claims description 2
- 210000004748 cultured cell Anatomy 0.000 claims 8
- 239000007858 starting material Substances 0.000 claims 5
- 210000004754 hybrid cell Anatomy 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 229940127557 pharmaceutical product Drugs 0.000 claims 4
- 241000699800 Cricetinae Species 0.000 claims 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 238000013329 compounding Methods 0.000 claims 1
- 239000000047 product Substances 0.000 description 21
- 238000001890 transfection Methods 0.000 description 11
- 239000000975 dye Substances 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 210000003463 organelle Anatomy 0.000 description 6
- 108091033409 CRISPR Proteins 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 239000003124 biologic agent Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000007910 cell fusion Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000799 fusogenic effect Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 241000711408 Murine respirovirus Species 0.000 description 3
- 229960000106 biosimilars Drugs 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000010079 rubber tapping Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 238000010453 CRISPR/Cas method Methods 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- AHZZHULAOVWYNO-RRKDMDGFSA-N N-hexanoylsphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC(=O)CCCCC)COP([O-])(=O)OCC[N+](C)(C)C AHZZHULAOVWYNO-RRKDMDGFSA-N 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000003163 cell fusion method Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000013373 clone screening Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000013337 sub-cultivation Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2019/036379 WO2020251537A1 (en) | 2019-06-10 | 2019-06-10 | Cell lines for high level production of protein-based pharmaceuticals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL288877A IL288877A (he) | 2022-07-01 |
| IL288877B1 true IL288877B1 (he) | 2024-01-01 |
Family
ID=73780999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL288877A IL288877B1 (he) | 2019-06-10 | 2019-06-10 | קווי תאים לייצור ברמה גבוהה של תרופות מבוססות חלבון |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3980524A4 (he) |
| JP (1) | JP2022543522A (he) |
| KR (1) | KR102648479B1 (he) |
| CN (1) | CN114096659A (he) |
| AU (1) | AU2019450349B2 (he) |
| BR (1) | BR112021024923A2 (he) |
| CA (1) | CA3143154A1 (he) |
| IL (1) | IL288877B1 (he) |
| WO (1) | WO2020251537A1 (he) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4912040A (en) * | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| CA2385102A1 (en) * | 1999-07-12 | 2001-01-18 | Genentech, Inc. | Expression vectors and methods |
| US7033781B1 (en) * | 1999-09-29 | 2006-04-25 | Diversa Corporation | Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating |
| WO2006027202A1 (en) * | 2004-09-06 | 2006-03-16 | Unite De Recherche En Biotherapie Et Oncologie (Rubio) | Generation of multiparent cell hybrids |
| US7351582B2 (en) * | 2005-06-17 | 2008-04-01 | Avigenics, Inc. | Cell lines |
| JP6297769B2 (ja) * | 2009-02-02 | 2018-03-20 | クロモセル コーポレーション | 新規の細胞株および方法 |
| US8778677B2 (en) * | 2009-06-10 | 2014-07-15 | BTS Research International PTY. Ltd. | Methods of generating hybrid/chimeric cells, and uses thereof |
| US10329594B1 (en) * | 2015-09-03 | 2019-06-25 | CHO Plus, Inc. | Cell lines for high level production of protein-based pharmaceuticals |
| WO2018232265A1 (en) * | 2017-06-16 | 2018-12-20 | Lonza Ltd | Universal self-regulating mammalian cell line platform for the production of biologics |
-
2019
- 2019-06-10 BR BR112021024923A patent/BR112021024923A2/pt unknown
- 2019-06-10 IL IL288877A patent/IL288877B1/he unknown
- 2019-06-10 CN CN201980097383.XA patent/CN114096659A/zh active Pending
- 2019-06-10 CA CA3143154A patent/CA3143154A1/en active Pending
- 2019-06-10 AU AU2019450349A patent/AU2019450349B2/en active Active
- 2019-06-10 EP EP19933147.1A patent/EP3980524A4/en active Pending
- 2019-06-10 KR KR1020227000886A patent/KR102648479B1/ko active IP Right Grant
- 2019-06-10 WO PCT/US2019/036379 patent/WO2020251537A1/en active Search and Examination
- 2019-06-10 JP JP2021573362A patent/JP2022543522A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL288877A (he) | 2022-07-01 |
| CA3143154A1 (en) | 2020-12-17 |
| KR20220024478A (ko) | 2022-03-03 |
| AU2019450349A1 (en) | 2022-01-27 |
| KR102648479B1 (ko) | 2024-03-15 |
| BR112021024923A2 (pt) | 2022-02-15 |
| AU2019450349B2 (en) | 2022-05-26 |
| JP2022543522A (ja) | 2022-10-13 |
| EP3980524A1 (en) | 2022-04-13 |
| CN114096659A (zh) | 2022-02-25 |
| WO2020251537A1 (en) | 2020-12-17 |
| EP3980524A4 (en) | 2023-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10329594B1 (en) | Cell lines for high level production of protein-based pharmaceuticals | |
| Gagliardi et al. | Characterization and transplantation of CD73-positive photoreceptors isolated from human iPSC-derived retinal organoids | |
| JP6043431B2 (ja) | 特異的な結合タンパク質または機能性タンパク質の遺伝子転位を利用した同定 | |
| JP5432117B2 (ja) | 宿主細胞中の組換えタンパク質の発現を増進するための組換え発現ベクター要素（ｒＥＶＥ） | |
| CN108368505A (zh) | 改善的flare(流式细胞术减弱报道蛋白表达)技术用于快速批量分选 | |
| JP6929877B2 (ja) | 免疫グロブリン産生の増強 | |
| EP2970915B1 (en) | Methods and compositions for generating stable transfected cells | |
| CN114085841B (zh) | 一种cho细胞基因nw_003614092.1内稳定表达蛋白质的位点及其应用 | |
| CN109906272A (zh) | 产生人抗体的非人动物和使用该非人动物的人抗体制作方法 | |
| CN114058625B (zh) | 一种cho细胞基因nw_003613781.1内稳定表达蛋白质的位点及其应用 | |
| CN116218782A (zh) | 细胞选择和修饰细胞代谢的方法 | |
| US20220243193A1 (en) | Cell lines for high level production of protein | |
| CN113969283B (zh) | 一种cho细胞基因nw_003613756.1内稳定表达蛋白质的位点及其应用 | |
| CN113969284B (zh) | 一种cho细胞基因nw_003614889.1内稳定表达蛋白质的位点及其应用 | |
| CN110551693A (zh) | 抗生素筛选hek细胞的方法 | |
| CN104870646B (zh) | 一种新颖的细胞系筛选方法 | |
| AU2019450349B2 (en) | Cell lines for high level production of protein-based pharmaceuticals | |
| CN108559727A (zh) | 一种促进山羊卵泡颗粒细胞增殖的方法 | |
| CN112175909A (zh) | 一株vsx2绿色荧光报告基因人诱导多能干细胞系及其构建方法 | |
| JP6469371B2 (ja) | 人工多能性幹細胞（ｉＰＳ細胞）から成る胚様体に複数の外来遺伝子を発現させる方法 | |
| CN112088213A (zh) | 人工重组的染色体及其用途 | |
| CN109402096A (zh) | 一种aid酶突变体及其应用 | |
| US20170233695A1 (en) | Cell Culture Media Composition and Methods of Producing Thereof | |
| CN103339255A (zh) | 蛋白质的生产方法 | |
| JP3415840B2 (ja) | 外来蛋白質の産生方法 |